LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial

  • The FDA has lifted the clinical hold on LogicBio Therapeutics Inc's LOGC LB-001 Investigational New Drug Application (IND) to resume patient enrollment in Phase 1/2 SUNRISE trial in pediatric methylmalonic acidemia patients. 
  • Methylmalonic acidemia is an inherited disorder in which the body cannot process certain proteins and fats (lipids) properly.
  • The FDA acknowledged that the company satisfactorily addressed all clinical hold issues in its letter. 
  • The company plans to start dosing in Q3 2022.
  • Related: Why Did LogicBio Therapeutics Shares Plunge To 52-Week Low Today?
  • In connection with the lifting of the clinical hold, LogicBio amended the SUNRISE protocol to reflect its dialogue with the FDA. 
  • LogicBio expects to proceed with dosing after implementing the changes to the SUNRISE protocol, which include enhanced monitoring measures and the use of a complement inhibitor if there are laboratory findings indicating a potential TMA. 
  • LogicBio plans to treat the next patients, who may be as young as six months old, at the 5e13 vg/kg dose and continually assess safety outcomes.
  • Outlook: LogicBio is reinstating its previous guidance and expects to present interim clinical data from the SUNRISE trial by the end of Q2 of 2022.
  • Price Action: LOGC shares are up 64.7% at $0.82 during the premarket session on the last check Monday.

Posted In: BriefsInformation TechnologySemiconductorswhy it's movingBiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.